Kean Woodmansey

Pharma perspectives: The role of digital and software solutions in pharmaceutical R&D

Mar 31, 2025 | Blogs, Pharma | 0 comments

It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.

Integration

Advanced analytical systems, like mass spectrometers and liquid chromatography systems, have a crucial role to play in guiding the pharmaceutical industry’s journey toward digital integration. We prioritize the development of expansive digital platforms that seamlessly merge various systems and data sources and establish robust standards. Embracing innovative technologies such as the internet of things and advanced analytics will allow us to implement real-time monitoring and predictive maintenance, ultimately optimizing operational efficiency for pharmaceutical companies.

Here is an example of An automated, real-time measurement of the kinetic hydrolysis of a glucuronide using the Echo® MS+ system with ZenoTOF 7600 system

Software

Embedding compliance features into our solutions is crucial to ensure alignment with evolving regulatory frameworks. Equally important, is a commitment to providing comprehensive training and continuous support to facilitate the smooth adoption of digital solutions within pharmaceutical companies. This proactive approach will empower our customers to navigate the complexities of digital transformation confidently and competently.

To allow our existing and potential new customers to trail our new software features, we provide a virtual trial of SCIEX OS software.

Ultimately, we should aim to drive the industry toward achieving operational excellence within the interconnected digital landscape. Through ongoing innovation and strategic partnership, life science technology providers can make a meaningful impact in shaping the future of pharmaceutical operations, ensuring agility, resilience, and efficacy in an increasingly digital world.

Learn more about how SCIEX can help here

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Antibody-drug conjugates (ADCs) are among the most promising—and analytically demanding—modalities in biopharma today. By combining large, heterogeneous antibodies with chemically labile payloads and linkers, ADCs introduce a level of structural complexity that challenges conventional analytical workflows. It also poses the challenge that the very features you need to measure are often the easiest to lose during analysis.

Six benefits of remote support every laboratory should know

Imagine having a tech expert at your fingertips to solve computer issues or a fitness trainer guiding you through workouts from the comfort of your home. In today’s fast-paced world, the ability to provide and receive service and support remotely is no longer a luxury but a necessity. Whether it’s troubleshooting a software issue, repairing a device, offering customer assistance, or enjoying the convenience of telehealth as a private individual, remote capabilities have revolutionized how businesses operate and how individuals get help

The costly consequences of unplanned downtime

Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.

Posted by

Kean Woodmansey

Senior Product Manager, Echo® MS+ system Kean Woodmansey is the Senior Product Manager for the Echo® MS system at SCIEX. In this role, he is responsible for the strategic success of the Echo MS+ portfolio. Kean spent the first part of his career working in contract research organizations, doing bioanalysis, before moving into pharma market development and product management.

0 Comments